NASDAQ:NITE - Nightstar Therapeutics Stock Price, Price Target & More

$14.34 -0.12 (-0.83 %)
(As of 04/24/2018 12:24 PM ET)
Previous Close$14.46
Today's Range$13.05 - $14.54
52-Week Range$10.01 - $24.93
Volume8,800 shs
Average Volume28,814 shs
Market Capitalization$406.33 million
P/E Ratio-8.80
Dividend YieldN/A
BetaN/A

About Nightstar Therapeutics (NASDAQ:NITE)

Nightstar Therapeutics logoNightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate includes NSR-REP1, a candidate that has completed Phase 1/2 clinical trial for the treatment of patients with choroideremia. It is also developing NSR-RPGR, a candidate that is in Phase 1/2 clinical trial for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy. The company was founded in 2013 and is headquartered in London, the United Kingdom.

Receive NITE News and Ratings via Email

Sign-up to receive the latest news and ratings for NITE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NITE
CUSIPN/A
Phone646-522-8445

Debt

Debt-to-Equity RatioN/A
Current Ratio14.38%
Quick Ratio14.38%

Price-To-Earnings

Trailing P/E Ratio-8.80
Forward P/E Ratio-7.88
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.48 per share
Price / Book3.20

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees23
Outstanding Shares28,100,000

How to Become a New Pot Stock Millionaire

Nightstar Therapeutics (NASDAQ:NITE) Frequently Asked Questions

What is Nightstar Therapeutics' stock symbol?

Nightstar Therapeutics trades on the NASDAQ under the ticker symbol "NITE."

When is Nightstar Therapeutics' next earnings date?

Nightstar Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, July, 3rd 2018. View Earnings Estimates for Nightstar Therapeutics.

What price target have analysts set for NITE?

6 brokerages have issued 12 month price objectives for Nightstar Therapeutics' stock. Their predictions range from $20.00 to $40.00. On average, they anticipate Nightstar Therapeutics' share price to reach $28.50 in the next year. View Analyst Ratings for Nightstar Therapeutics.

What are Wall Street analysts saying about Nightstar Therapeutics stock?

Here are some recent quotes from research analysts about Nightstar Therapeutics stock:
  • 1. According to Zacks Investment Research, "Nightstar Therapeutics Limited is a clinical-stage gene therapy company. It focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases including choroideremia, X-linked retinitis pigmentosa and Best vitelliform macular dystrophy. The company operates primarily in North America and Europe. Nightstar Therapeutics Limited is based in LONDON, United Kingdom. " (4/7/2018)
  • 2. Mizuho analysts commented, "We are less concerned about financial performance than progress in the pipeline. In our view, Nightstar has the most comprehensive data in Choroideremia (CHM) in the gene therapy space. The phase 3 STAR trial of NSR-REP1 in CHM was recently initiated and could be adequate to support a BLA filing in 2020." (4/5/2018)

Who are some of Nightstar Therapeutics' key competitors?

Who are Nightstar Therapeutics' key executives?

Nightstar Therapeutics' management team includes the folowing people:
  • Mr. David Fellows, CEO & Director (Age 61)
  • Mr. Senthil Sundaram, CFO & Principal Accounting Officer (Age 40)
  • Dr. Gregory Robinson Ph.D., Chief Scientific Officer (Age 59)
  • Mr. Aniz Girach, Chief Medical Officer
  • Dr. Tuyen Ong M.D., MRCOphth, MBA, Exec. VP & Chief Devel. Officer (Age 43)

When did Nightstar Therapeutics IPO?

(NITE) raised $76 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and Chardan were co-managers.

When did the company's lock-up period expire?

Nightstar Therapeutics' lock-up period expired on Tuesday, March 27th. Nightstar Therapeutics had issued 5,360,000 shares in its public offering on September 28th. The total size of the offering was $75,040,000 based on an initial share price of $14.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the end of the lock-up period.

Has Nightstar Therapeutics been receiving favorable news coverage?

News articles about NITE stock have trended somewhat positive this week, according to Accern. The research firm identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Nightstar Therapeutics earned a coverage optimism score of 0.09 on Accern's scale. They also gave headlines about the company an impact score of 47.17 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of Nightstar Therapeutics?

Shares of NITE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nightstar Therapeutics' stock price today?

One share of NITE stock can currently be purchased for approximately $14.34.

How big of a company is Nightstar Therapeutics?

Nightstar Therapeutics has a market capitalization of $406.33 million. The company earns $-29,680,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. Nightstar Therapeutics employs 23 workers across the globe.

How can I contact Nightstar Therapeutics?

Nightstar Therapeutics' mailing address is 81 HARTWELL AVE. SUITE 100, LEXINGTON MA, 02421. The company can be reached via phone at 646-522-8445 or via email at [email protected]


MarketBeat Community Rating for Nightstar Therapeutics (NITE)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  74 (Vote Outperform)
Underperform Votes:  52 (Vote Underperform)
Total Votes:  126
MarketBeat's community ratings are surveys of what our community members think about Nightstar Therapeutics and other stocks. Vote "Outperform" if you believe NITE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NITE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Nightstar Therapeutics (NASDAQ:NITE) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Nightstar Therapeutics in the last 12 months. Their average twelve-month price target is $28.50, suggesting that the stock has a possible upside of 98.74%. The high price target for NITE is $40.00 and the low price target for NITE is $20.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $28.50$28.50$30.20$24.75
Price Target Upside: 98.74% upside96.82% upside106.71% upsideN/A

Nightstar Therapeutics (NASDAQ:NITE) Consensus Price Target History

Price Target History for Nightstar Therapeutics (NASDAQ:NITE)

Nightstar Therapeutics (NASDAQ:NITE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/5/2018WedbushReiterated RatingOutperform$31.00HighView Rating Details
4/5/2018MizuhoReiterated RatingBuy$20.00HighView Rating Details
1/3/2018Chardan CapitalInitiated CoverageBuy -> Buy$40.00HighView Rating Details
10/23/2017Leerink SwannInitiated CoverageOutperform -> Outperform$25.00N/AView Rating Details
10/23/2017Jefferies GroupInitiated CoverageBuy -> Buy$25.00N/AView Rating Details
10/23/2017BMO Capital MarketsInitiated CoverageOutperform$30.00N/AView Rating Details
(Data available from 4/24/2016 forward)

Earnings

Dividends

Nightstar Therapeutics (NASDAQ:NITE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Nightstar Therapeutics (NASDAQ NITE) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 29.06%
Insider Trading History for Nightstar Therapeutics (NASDAQ:NITE)
Institutional Ownership by Quarter for Nightstar Therapeutics (NASDAQ:NITE)

Nightstar Therapeutics (NASDAQ NITE) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Nightstar Therapeutics (NASDAQ NITE) News Headlines

Source:
DateHeadline
Nightstar Therapeutics to Present New Data in Choroideremia at the ARVO 2018 Annual MeetingNightstar Therapeutics to Present New Data in Choroideremia at the ARVO 2018 Annual Meeting
feeds.benzinga.com - April 23 at 7:30 AM
Nightstar Therapeutics to Post FY2020 Earnings of ($1.59) Per Share, Leerink Swann Forecasts (NITE)Nightstar Therapeutics to Post FY2020 Earnings of ($1.59) Per Share, Leerink Swann Forecasts (NITE)
www.americanbankingnews.com - April 23 at 2:50 AM
Nightstar Therapeutics (NITE) Given Average Rating of "Buy" by BrokeragesNightstar Therapeutics (NITE) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 18 at 8:41 AM
-$0.39 EPS Expected for Nightstar Therapeutics (NITE) This Quarter-$0.39 EPS Expected for Nightstar Therapeutics (NITE) This Quarter
www.americanbankingnews.com - April 16 at 11:14 AM
Nightstar Therapeutics (NITE) Expected to Post Q2 2018 Earnings of ($0.77) Per ShareNightstar Therapeutics (NITE) Expected to Post Q2 2018 Earnings of ($0.77) Per Share
www.americanbankingnews.com - April 16 at 2:08 AM
Reviewing Fennec Pharmaceuticals (FENC) & Nightstar Therapeutics (NITE)Reviewing Fennec Pharmaceuticals (FENC) & Nightstar Therapeutics (NITE)
www.americanbankingnews.com - April 11 at 9:59 AM
Wedbush Weighs in on Nightstar Therapeutics Q1 2018 Earnings (NITE)Wedbush Weighs in on Nightstar Therapeutics' Q1 2018 Earnings (NITE)
www.americanbankingnews.com - April 9 at 1:21 AM
Nightstar Therapeutics (NITE) Cut to "Sell" at Zacks Investment ResearchNightstar Therapeutics (NITE) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 7 at 9:28 AM
Nightstar Therapeutics (NITE) Receives New Coverage from Analysts at Leerink SwannNightstar Therapeutics (NITE) Receives New Coverage from Analysts at Leerink Swann
www.americanbankingnews.com - April 6 at 12:11 PM
Nightstar Therapeutics (NITE) Earns Outperform Rating from Analysts at WedbushNightstar Therapeutics (NITE) Earns Outperform Rating from Analysts at Wedbush
www.americanbankingnews.com - April 6 at 11:00 AM
Nightstar Therapeutics (NITE) Research Coverage Started at BMO Capital MarketsNightstar Therapeutics (NITE) Research Coverage Started at BMO Capital Markets
www.americanbankingnews.com - April 6 at 10:59 AM
Nightstar Therapeutics (NITE) Earns Buy Rating from Analysts at Jefferies GroupNightstar Therapeutics (NITE) Earns Buy Rating from Analysts at Jefferies Group
www.americanbankingnews.com - April 6 at 10:58 AM
FY2022 Earnings Estimate for Nightstar Therapeutics Issued By Wedbush (NITE)FY2022 Earnings Estimate for Nightstar Therapeutics Issued By Wedbush (NITE)
www.americanbankingnews.com - April 6 at 8:23 AM
Nightstar Therapeutics Forecasted to Earn FY2018 Earnings of ($2.11) Per Share (NITE)Nightstar Therapeutics Forecasted to Earn FY2018 Earnings of ($2.11) Per Share (NITE)
www.americanbankingnews.com - April 6 at 6:54 AM
Nightstar Therapeutics (NITE) Earns Outperform Rating from WedbushNightstar Therapeutics (NITE) Earns Outperform Rating from Wedbush
www.americanbankingnews.com - April 5 at 1:43 PM
Nightstar Therapeutics (NITE) Receives "Buy" Rating from MizuhoNightstar Therapeutics (NITE) Receives "Buy" Rating from Mizuho
www.americanbankingnews.com - April 5 at 9:53 AM
Jefferies Group Comments on Nightstar Therapeutics Q1 2018 Earnings (NITE)Jefferies Group Comments on Nightstar Therapeutics' Q1 2018 Earnings (NITE)
www.americanbankingnews.com - April 5 at 8:36 AM
BRIEF-Nightstar Therapeutics Reports 2017 Financial ResultsBRIEF-Nightstar Therapeutics Reports 2017 Financial Results
www.reuters.com - April 4 at 4:44 PM
Synconas Nightstar 2017 Loss Widens On Research And Development CostsSyncona's Nightstar 2017 Loss Widens On Research And Development Costs
www.morningstar.co.uk - April 4 at 4:44 PM
Syncona Limited - Nightstar Reports 2017 Financial ResultsSyncona Limited - Nightstar Reports 2017 Financial Results
www.finanznachrichten.de - April 4 at 4:44 PM
Nightstar Therapeutics Reports 2017 Financial Results and Business HighlightsNightstar Therapeutics Reports 2017 Financial Results and Business Highlights
feeds.benzinga.com - April 3 at 5:58 PM
 Brokerages Expect Nightstar Therapeutics PLC (NITE) to Post -$0.20 EPS Brokerages Expect Nightstar Therapeutics PLC (NITE) to Post -$0.20 EPS
www.americanbankingnews.com - March 30 at 1:18 PM
Nightstar Therapeutics (NITE) Earns Buy Rating from Analysts at MizuhoNightstar Therapeutics (NITE) Earns Buy Rating from Analysts at Mizuho
www.americanbankingnews.com - March 24 at 10:38 PM
Nightstar Therapeutics PLC (NITE) Given Consensus Recommendation of "Buy" by BrokeragesNightstar Therapeutics PLC (NITE) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 24 at 8:04 AM
Cryptanite Blockchain Technologies Corp. Goes Public on Canadian Securities ExchangeCryptanite Blockchain Technologies Corp. Goes Public on Canadian Securities Exchange
finance.yahoo.com - March 22 at 4:53 PM
Nightstar Therapeutics PLCs (NITE) Lock-Up Period Will Expire  on March 27thNightstar Therapeutics PLC's (NITE) Lock-Up Period Will Expire on March 27th
www.americanbankingnews.com - March 20 at 1:16 AM
CSE New Listing - Cryptanite Blockchain Technologies Commences Trading on the Canadian Securities Exchange - Video News Alert on Investmentpitch.comCSE New Listing - Cryptanite Blockchain Technologies Commences Trading on the Canadian Securities Exchange - Video News Alert on Investmentpitch.com
finance.yahoo.com - March 15 at 4:43 PM
Nightstar Therapeutics PLC (NITE) Short Interest Up 33.0% in FebruaryNightstar Therapeutics PLC (NITE) Short Interest Up 33.0% in February
www.americanbankingnews.com - March 13 at 1:54 AM
IIROC Trading Halt - NITEIIROC Trading Halt - NITE
finance.yahoo.com - March 12 at 4:44 PM
IIROC Trade Resumption - NITEIIROC Trade Resumption - NITE
finance.yahoo.com - March 12 at 4:44 PM
Nightstar Therapeutics (NITE) Receives Outperform Rating from WedbushNightstar Therapeutics (NITE) Receives Outperform Rating from Wedbush
www.americanbankingnews.com - March 7 at 4:36 PM
BRIEF-Nightstar Therapeutics Starts Star Phase 3 Registrational Trial For Nsr-Rep1 In ChoroideremiaBRIEF-Nightstar Therapeutics Starts Star Phase 3 Registrational Trial For Nsr-Rep1 In Choroideremia
www.reuters.com - March 5 at 10:21 AM
Synconas Nightstar Begins NSR-REP1 Trial And Appoints New DirectorSyncona's Nightstar Begins NSR-REP1 Trial And Appoints New Director
www.morningstar.co.uk - March 5 at 10:21 AM
Syncona Limited - Nightstar initiates Pivotal Trial in ChoroideremiaSyncona Limited - Nightstar initiates Pivotal Trial in Choroideremia
www.finanznachrichten.de - March 5 at 10:21 AM
Nightstar Therapeutics Announces Initiation of STAR Phase 3 Registrational Trial for NSR-REP1 in ChoroideremiaNightstar Therapeutics Announces Initiation of STAR Phase 3 Registrational Trial for NSR-REP1 in Choroideremia
finance.yahoo.com - March 5 at 10:21 AM
Nightstar Therapeutics PLC (NITE) Receives Average Recommendation of "Buy" from AnalystsNightstar Therapeutics PLC (NITE) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - February 27 at 9:52 AM
-$0.20 Earnings Per Share Expected for Nightstar Therapeutics PLC (NITE) This Quarter-$0.20 Earnings Per Share Expected for Nightstar Therapeutics PLC (NITE) This Quarter
www.americanbankingnews.com - February 24 at 2:00 PM
 Nightstar Therapeutics PLC (NITE) Given Average Recommendation of "Strong Buy" by Analysts Nightstar Therapeutics PLC (NITE) Given Average Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - February 13 at 1:44 PM
Brokerages Anticipate Nightstar Therapeutics PLC (NITE) to Post ($0.19) EPSBrokerages Anticipate Nightstar Therapeutics PLC (NITE) to Post ($0.19) EPS
www.americanbankingnews.com - February 10 at 3:28 PM
Zacks: Nightstar Therapeutics PLC (NITE) Given Consensus Recommendation of "Strong Buy" by BrokeragesZacks: Nightstar Therapeutics PLC (NITE) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - February 6 at 10:40 AM
Zacks: Nightstar Therapeutics PLC (NITE) Given Average Recommendation of "Strong Buy" by BrokeragesZacks: Nightstar Therapeutics PLC (NITE) Given Average Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - January 30 at 7:56 AM
 Analysts Expect Nightstar Therapeutics PLC (NITE) Will Post Earnings of -$0.19 Per Share Analysts Expect Nightstar Therapeutics PLC (NITE) Will Post Earnings of -$0.19 Per Share
www.americanbankingnews.com - January 21 at 3:25 PM
Brokerages Anticipate Nightstar Therapeutics PLC (NITE) to Announce ($0.19) EPSBrokerages Anticipate Nightstar Therapeutics PLC (NITE) to Announce ($0.19) EPS
www.americanbankingnews.com - January 20 at 9:36 PM
Nightstar Therapeutics PLC (NITE) Forecasted to Post FY2021 Earnings of ($1.18) Per ShareNightstar Therapeutics PLC (NITE) Forecasted to Post FY2021 Earnings of ($1.18) Per Share
www.americanbankingnews.com - January 19 at 11:22 PM
Wedbush Weighs in on Nightstar Therapeutics PLCs FY2022 Earnings (NITE)Wedbush Weighs in on Nightstar Therapeutics PLC's FY2022 Earnings (NITE)
www.americanbankingnews.com - January 18 at 11:32 PM
Nightstar Therapeutics (NITE) Price Target Raised to $31.00 at WedbushNightstar Therapeutics (NITE) Price Target Raised to $31.00 at Wedbush
www.americanbankingnews.com - January 18 at 12:08 AM
Zacks: Brokerages Set $27.80 Target Price for Nightstar Therapeutics PLC (NITE)Zacks: Brokerages Set $27.80 Target Price for Nightstar Therapeutics PLC (NITE)
www.americanbankingnews.com - January 5 at 5:50 PM
Nightstar Therapeutics (NITE) Receives New Coverage from Analysts at Chardan CapitalNightstar Therapeutics (NITE) Receives New Coverage from Analysts at Chardan Capital
www.americanbankingnews.com - January 3 at 6:24 PM
Zacks: Nightstar Therapeutics PLC (NITE) Receives Average Rating of "Strong Buy" from BrokeragesZacks: Nightstar Therapeutics PLC (NITE) Receives Average Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - January 2 at 9:42 PM
Nightstar Therapeutics (NITE) and Its Competitors Financial SurveyNightstar Therapeutics (NITE) and Its Competitors Financial Survey
www.americanbankingnews.com - December 29 at 5:28 AM

SEC Filings

Nightstar Therapeutics (NASDAQ:NITE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Nightstar Therapeutics (NASDAQ:NITE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Nightstar Therapeutics (NASDAQ NITE) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.